CAR T-Cell Therapy for Non-Hodgkin's Lymphoma
Trial Summary
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment 19(T2)28z1xx TRAC T cell for Non-Hodgkin's Lymphoma?
Research shows that CAR T-cell therapy, which is a type of treatment that uses modified immune cells to target cancer, has been effective in treating aggressive B-cell non-Hodgkin lymphoma, especially in patients who do not respond to standard treatments. This therapy has been approved for use in relapsed or chemotherapy-resistant B-cell non-Hodgkin lymphoma, demonstrating its potential to induce complete and lasting responses.12345
What makes the CAR T-cell treatment 19(T2)28z1xx TRAC T cell unique for non-Hodgkin's lymphoma?
CAR T-cell therapy is a novel treatment for non-Hodgkin's lymphoma that involves modifying a patient's own immune cells to better recognize and attack cancer cells. This approach is particularly promising for patients who do not respond to standard treatments, offering a new option for those with aggressive or resistant forms of the disease.13467
What is the purpose of this trial?
The purpose of this research is to evaluate if study therapy, 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells, may be an effective treatment for people with relapsed/refractory B-cell lymphoma. Researchers will also evaluate if this study therapy is safe, and to look for the highest dose that causes few or mild side effects in participants.
Research Team
Jae Park, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Adults over 18 with certain types of B-cell lymphoma that haven't responded to or have returned after treatment, including chemotherapy. Participants must have adequate kidney, liver, and heart function, no active CNS disease or other cancers requiring therapy beyond observation or hormones (except skin cancer), and not be pregnant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive escalating doses of 19(T2)28z1xx TRAC-chimeric antigen receptor (CAR) T cells
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 19(T2)28z1xx TRAC T cell
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor
Takeda
Industry Sponsor
Dr. Naoyoshi Hirota
Takeda
Chief Medical Officer since 2020
MD from University of Tokyo
Christophe Weber
Takeda
Chief Executive Officer since 2015
PhD in Molecular Biology from Université de Montpellier